Essential Medicines and Biologicals
Medicines and Health Technologies
Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (EGPA)
After the approval in May 2008 within the framework of the 61st World Health Assembly of the Resolution WHA61.21, Global strategy and plan of action on public health, innovation and intellectual property (GSPA). The important role played by the Region of the Americas in the negotiation and the institutional attendance of PAHO in the process resulted in the adoption of the Resolution CD. 48R15, Global Strategy on Public Health, Innovation and Intellectual Property: a Regional Perspective which identifies three interrelated and complementary key elements of work through which the strategy is implemented and this is framed within the group of actions of technical cooperation of the organization: access, management of intellectual property rights, and technological innovation.
for more information, please click here
Conceptual map on Public Health and Intellectual Property (MC SPPI)
Within the framework of the Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual Property (GSPA) contended in Resolution WHA61.21 of the World Health Organization (WHO) and the Regional Perspective on Public Health, Innovation and Intellectual Property adopted in Resolution CD.48.R15 it is proposed as a need establishing a framework of analysis that offers an objective diagnostic that facilitates the action of state authorities, improving the efficiency of its programs and the effectiveness of its actions in the promotion of access to drugs with regard to the management of Intellectual Property Rights (IPR). For this purpose it is judged equally necessary to understand the institutional operation of various actors with responsibility on this topic, either state institutions or private entities.
1. Compile coherently the legal framework and regulatory body currently in effect in the area of management of DPI and Public Health that impacts on access to drugs for the population of Latin American States.
2. Suggest possible reforms, improvements, and modifications in the legal and regulatory law that permits a reduction in public spending and an improvement of the efficiency and effectiveness indicators of public actions within the area of access to drugs.
3. Identify the different agents with incidence (direct and indirect) in access to drugs. Ad well as their relationship (coordination, subordination and supervision)
4. Establish comparable patterns, both within the legal framework and in the institutional arrangement between countries and sub.-regional groupings.